Comparison 7. OKT3 versus placebo/no induction.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Main outcomes	12		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 Death at 1 to 2 years	6	491	Risk Ratio (M‐H, Random, 95% CI)	0.41 [0.18, 0.97]
1.2 Death at 3 to 5 years	5	768	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.37, 1.44]
1.3 Graft loss (all cause) at 1 to 2 years	7	416	Risk Ratio (M‐H, Random, 95% CI)	0.55 [0.30, 1.02]
1.4 Graft loss (all cause) at 3 to 5 years	5	768	Risk Ratio (M‐H, Random, 95% CI)	0.73 [0.47, 1.14]
1.5 Acute rejection, any episode (+ CNI)	8	968	Risk Ratio (M‐H, Random, 95% CI)	0.60 [0.43, 0.83]
1.6 Acute rejection at 3 months (no CNI)	3	85	Risk Ratio (M‐H, Random, 95% CI)	0.70 [0.33, 1.46]
1.7 Delayed graft function	6	494	Risk Ratio (M‐H, Random, 95% CI)	1.08 [0.70, 1.65]
2 Other adverse effects	6		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
2.1 Infection (all cause)	1	108	Risk Ratio (M‐H, Random, 95% CI)	1.38 [1.04, 1.82]
2.2 Bacterial infection	3	366	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.76, 1.34]
2.3 Viral infection (all cause)	2	353	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.72, 1.37]
2.4 CMV infection	3	332	Risk Ratio (M‐H, Random, 95% CI)	1.52 [0.82, 2.84]
2.5 HSV infection	1	215	Risk Ratio (M‐H, Random, 95% CI)	1.45 [0.89, 2.38]
2.6 Fungal infection	3	568	Risk Ratio (M‐H, Random, 95% CI)	1.26 [0.33, 4.89]
2.7 Malignancy or PTLD	3	610	Risk Ratio (M‐H, Random, 95% CI)	1.34 [0.52, 3.50]
3 Serum creatinine	5		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 3 months	3	226	Mean Difference (IV, Random, 95% CI)	‐0.93 [‐15.78, 13.93]
3.2 1 year	2	261	Mean Difference (IV, Random, 95% CI)	‐6.22 [‐18.21, 5.76]
3.3 3 to 4 years	2	38	Mean Difference (IV, Random, 95% CI)	‐21.10 [‐49.81, 7.61]